275.60
0.94%
-2.61
Pre-market:
275.60
Bio-Rad Laboratories Inc. stock is currently priced at $275.60, with a 24-hour trading volume of 161.67K.
It has seen a -0.94% decreased in the last 24 hours and a -19.20% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $280.3 pivot point. If it approaches the $275.3 support level, significant changes may occur.
Previous Close:
$278.21
Open:
$277.88
24h Volume:
161.67K
Market Cap:
$7.86B
Revenue:
$2.67B
Net Income/Loss:
$-637.32M
P/E Ratio:
-47.11
EPS:
-5.85
Net Cash Flow:
$218.26M
1W Performance:
-1.93%
1M Performance:
-19.20%
6M Performance:
-4.99%
1Y Performance:
-36.97%
Bio-Rad Laboratories Inc. Stock (BIO) Company Profile
Name
Bio-Rad Laboratories Inc.
Sector
Industry
Phone
510-724-7000
Address
1000 Alfred Nobel Drive, Hercules
Bio-Rad Laboratories Inc. Stock (BIO) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Dec-07-23 | Initiated | UBS | Buy |
Jun-16-23 | Initiated | Wells Fargo | Overweight |
Dec-07-22 | Initiated | RBC Capital Mkts | Outperform |
Aug-25-22 | Initiated | Credit Suisse | Outperform |
Jan-28-22 | Reiterated | Citigroup | Buy |
Jan-08-20 | Initiated | Wells Fargo | Overweight |
Jan-07-20 | Initiated | Citigroup | Buy |
Oct-17-18 | Initiated | Goldman | Buy |
Sep-20-18 | Initiated | Morgan Stanley | Equal-Weight |
Feb-16-18 | Downgrade | CL King | Buy → Neutral |
Jul-13-17 | Initiated | Wells Fargo | Outperform |
Jun-28-17 | Upgrade | Deutsche Bank | Hold → Buy |
Jan-18-17 | Initiated | Deutsche Bank | Hold |
Oct-13-16 | Initiated | CL King | Buy |
May-06-15 | Reiterated | Jefferies | Buy |
Dec-18-09 | Initiated | Maxim Group | Buy |
Nov-06-09 | Initiated | Jefferies & Co | Buy |
Jul-17-09 | Initiated | Soleil | Buy |
Sep-26-07 | Initiated | Banc of America Sec | Buy |
Feb-23-07 | Downgrade | Robert W. Baird | Outperform → Neutral |
View All
Bio-Rad Laboratories Inc. Stock (BIO) Latest News
New Strong Sell Stocks for April 19th
Zacks Investment Research
96% Of S&P 500 Stocks Show Upside Potential Vs. Street Estimates: Which Offers The Best Opportunity?
Benzinga
Bio-Rad Laboratories (BIO) to Post Q1 Earnings: What Awaits?
Zacks Investment Research
Bio-Rad (BIO) Hurt by Softness in BioPharma and Competition
Zacks Investment Research
Waters (WAT) Boosts Waters Operating Segment With HPLC System
Zacks Investment Research
Why Is Perrigo (PRGO) Up 19.1% Since Last Earnings Report?
Zacks Investment Research
Bio-Rad Laboratories Inc. Stock (BIO) Financials Data
Bio-Rad Laboratories Inc. (BIO) Revenue 2024
BIO reported a revenue (TTM) of $2.67 billion for the quarter ending December 31, 2023, a -4.67% decline year-over-year.
Bio-Rad Laboratories Inc. (BIO) Net Income 2024
BIO net income (TTM) was -$637.32 million for the quarter ending December 31, 2023, a +82.43% increase year-over-year.
Bio-Rad Laboratories Inc. (BIO) Cash Flow 2024
BIO recorded a free cash flow (TTM) of $218.26 million for the quarter ending December 31, 2023, a +171.84% increase year-over-year.
Bio-Rad Laboratories Inc. (BIO) Earnings per Share 2024
BIO earnings per share (TTM) was -$21.49 for the quarter ending December 31, 2023, a +82.28% growth year-over-year.
Bio-Rad Laboratories Inc. Stock (BIO) Insider Trading
Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
---|---|---|---|---|---|---|---|
ERNST TIMOTHY S | EVP, General Counsel & Sec |
Feb 28 '24 |
Option Exercise |
326.15 |
2,500 |
815,375 |
5,897 |
ERNST TIMOTHY S | EVP, General Counsel & Sec |
Feb 28 '24 |
Sale |
330.55 |
2,500 |
826,375 |
3,397 |
Crowley Michael | EVP, GBL Commercial Operations |
Feb 27 '24 |
Option Exercise |
215.98 |
3,000 |
647,940 |
9,942 |
Crowley Michael | EVP, GBL Commercial Operations |
Feb 27 '24 |
Sale |
336.00 |
3,000 |
1,008,000 |
6,942 |
WRIGHT DARA | EVP, President, CDG |
Dec 16 '23 |
Option Exercise |
0.00 |
502 |
0 |
2,001 |
WRIGHT DARA | EVP, President, CDG |
Dec 12 '23 |
Sale |
299.16 |
1,200 |
358,992 |
1,499 |
Crowley Michael | EVP, GBL Commercial Operations |
Nov 28 '23 |
Sale |
305.10 |
642 |
195,874 |
6,942 |
SCHWARTZ NORMAN D | Chairman, President, and CEO |
Nov 01 '23 |
Option Exercise |
133.57 |
66,000 |
8,815,760 |
380,300 |
Dahowski Diane | EVP, Global Supply Chain |
Sep 04 '23 |
Option Exercise |
0.00 |
600 |
0 |
12,155 |
COREY COLLEEN | EVP, Global Human Resources |
Sep 04 '23 |
Option Exercise |
0.00 |
600 |
0 |
17,431 |
About Bio-Rad Laboratories Inc.
Bio-Rad Laboratories, Inc. develops, manufactures, and markets products and solutions for the life science research and clinical diagnostic markets in Europe, the Pacific Rim, the United States, and internationally. The company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. It operates through two segments, Life Science and Clinical Diagnostics. The Life Science segment develops, manufactures, and markets a range of reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cell biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, transfusion laboratories, and insurance and forensic testing laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.
Cap:
|
Volume (24h):